TY - JOUR
T1 - Seroepidemiology for Enteric Fever
T2 - Emerging Approaches and Opportunities
AU - Aiemjoy, Kristen
AU - Seidman, Jessica C.
AU - Charles, Richelle C.
AU - Andrews, Jason R.
N1 - Funding Information: Financial support. The Bill & Melinda Gates Foundation; NIH NIAID (K01 TW012177). Funding Information: Supplement sponsorship. This article appears as part of the supplement “Charting the Course to Meet the Challenges Ahead: Research and Developments on Typhoid and Other Invasive Salmonelloses” sponsored by the Coalition against Typhoid Secretariat, housed at the Sabin Vaccine Institute in Washington, DC and made possible by a grant from the Bill & Melinda Gates Foundation. Publisher Copyright: © 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Safe and effective typhoid conjugate vaccines (TCVs) are available, but many countries lack the high-resolution data needed to prioritize TCV introduction to the highest-risk communities. Here we discuss seroepidemiology - an approach using antibody response data to characterize infection burden - as a potential tool to fill this data gap. Serologic tests for typhoid have existed for over a hundred years, but only recently were antigens identified that were sensitive and specific enough to use as epidemiologic markers. These antigens, coupled with new methodological developments, permit estimating seroincidence - the rate at which new infections occur in a population - from cross-sectional serosurveys. These new tools open up many possible applications for enteric fever seroepidemiology, including generating high-resolution surveillance data, monitoring vaccine impact, and integrating with other serosurveillance initiatives. Challenges remain, including distinguishing Salmonella Typhi from Salmonella Paratyphi infections and accounting for reinfections. Enteric fever seroepidemiology can be conducted at a fraction of the cost, time, and sample size of surveillance blood culture studies and may enable more efficient and scalable surveillance for this important infectious disease.
AB - Safe and effective typhoid conjugate vaccines (TCVs) are available, but many countries lack the high-resolution data needed to prioritize TCV introduction to the highest-risk communities. Here we discuss seroepidemiology - an approach using antibody response data to characterize infection burden - as a potential tool to fill this data gap. Serologic tests for typhoid have existed for over a hundred years, but only recently were antigens identified that were sensitive and specific enough to use as epidemiologic markers. These antigens, coupled with new methodological developments, permit estimating seroincidence - the rate at which new infections occur in a population - from cross-sectional serosurveys. These new tools open up many possible applications for enteric fever seroepidemiology, including generating high-resolution surveillance data, monitoring vaccine impact, and integrating with other serosurveillance initiatives. Challenges remain, including distinguishing Salmonella Typhi from Salmonella Paratyphi infections and accounting for reinfections. Enteric fever seroepidemiology can be conducted at a fraction of the cost, time, and sample size of surveillance blood culture studies and may enable more efficient and scalable surveillance for this important infectious disease.
KW - disease burden
KW - enteric fever
KW - seroepidemiology
KW - serosurveillance
KW - typhoid
UR - http://www.scopus.com/inward/record.url?scp=85163116935&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/ofid/ofad021
DO - https://doi.org/10.1093/ofid/ofad021
M3 - Article
C2 - 37274530
SN - 2328-8957
VL - 10
SP - S21-S25
JO - Open forum infectious diseases
JF - Open forum infectious diseases
ER -